Accolade, Inc. (NASDAQ:ACCD) Receives $6.51 Consensus PT from Analysts

Shares of Accolade, Inc. (NASDAQ:ACCD) have been given a consensus recommendation of “Hold” by the fourteen research firms that are presently covering the company, Marketbeat.com reports. Thirteen research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $6.51.

Several analysts have commented on the company. Raymond James restated a “market perform” rating on shares of Accolade in a report on Thursday, January 9th. Morgan Stanley reduced their price objective on Accolade from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Leerink Partners reaffirmed a “market perform” rating on shares of Accolade in a research note on Wednesday, January 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Accolade in a research note on Wednesday, January 8th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $7.03 price objective on shares of Accolade in a research note on Wednesday, February 12th.

Hedge Funds Weigh In On Accolade

Several hedge funds and other institutional investors have recently bought and sold shares of ACCD. Johnson Financial Group LLC acquired a new position in Accolade during the 3rd quarter worth approximately $1,642,000. GSA Capital Partners LLP raised its position in shares of Accolade by 41.3% in the 3rd quarter. GSA Capital Partners LLP now owns 460,052 shares of the company’s stock valued at $1,771,000 after purchasing an additional 134,427 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Accolade by 167.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,723 shares of the company’s stock valued at $1,327,000 after purchasing an additional 215,958 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Accolade in the 3rd quarter valued at approximately $96,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Accolade by 4.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,201 shares of the company’s stock valued at $2,191,000 after purchasing an additional 26,155 shares in the last quarter. 84.99% of the stock is owned by institutional investors and hedge funds.

Accolade Trading Up 0.3 %

Accolade stock opened at $6.98 on Thursday. The stock has a market cap of $572.31 million, a PE ratio of -3.10 and a beta of 2.18. The stock has a 50-day moving average price of $6.63 and a 200 day moving average price of $4.73. Accolade has a 52 week low of $3.08 and a 52 week high of $10.68. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67.

Accolade (NASDAQ:ACCD) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. Equities research analysts predict that Accolade will post -1.2 earnings per share for the current fiscal year.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.